Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
Chronic hepatitis B (CHB) is a long-term infection caused by the hepatitis B virus that can lead to progressive liver damage, cirrhosis, and hepatocellular carcinoma. As per the Centers for Disease Control and Prevention (CDC), an estimated 1.2 million people were newly infected with hepatitis B virus (HBV) in 2022, while chronic hepatitis B and chronic hepatitis C collectively caused 1.3 million deaths annually due to liver disease and liver cancer. According to the chronic hepatitis B (CHB) epidemiology forecast by Expert Market Research, the disease burden is expected to remain substantial, emphasizing the need for improved liver disease prevention, diagnosis, and treatment strategies.
2025
Base Year
2019-2025
Historical Period
2026-2035
Forecast Period
Read more about this report - Request a Free Sample
Chronic Hepatitis B (CHB) Epidemiology Forecast Report Coverage
Expert Market Research's “Chronic Hepatitis B (CHB) Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of chronic hepatitis B (CHB). It projects the future incidence and prevalence rates of chronic hepatitis B (CHB) cases across various populations. The study covers age, gender, and type as major determinants of the chronic hepatitis B (CHB) population. The report highlights patterns in the prevalence of chronic hepatitis B (CHB) over time and projects future trends based on multiple variables.
The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of chronic hepatitis B (CHB) in the 8 major markets.
Regions Covered
- United States
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
Chronic Hepatitis B (CHB) Understanding: Disease Overview
Chronic hepatitis B (CHB) is a long-term viral liver infection caused by the hepatitis B virus (HBV) that persists for more than six months. The infection occurs when the body's immune system is unable to eliminate the virus, allowing ongoing viral replication and liver inflammation. CHB is commonly transmitted through exposure to infected blood, sexual contact, or from an infected mother to her child during childbirth. The disease is generally classified into different clinical phases based on viral activity and immune response. Without appropriate management, liver fibrosis may progress to cirrhosis, liver failure, or hepatocellular carcinoma.
Key Report Insights
|
Parameter |
Insight |
|
Largest Patient Pool |
India |
|
Fastest Growing Region |
India |
|
High-Risk Population |
Individuals infected at birth or during early childhood, immunocompromised individuals, and people with chronic liver disease |
|
Key Diagnostic Method |
Hepatitis B surface antigen (HBsAg) testing with HBV DNA quantification |
|
Major Risk Factor |
Perinatal transmission and exposure to infected blood or body fluids |
|
Major gap in the market |
Underdiagnosis due to limited screening and delayed disease detection |
Chronic Hepatitis B (CHB) Epidemiology Perspective
The chronic hepatitis B (CHB) epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the chronic hepatitis B (CHB) epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for chronic hepatitis B (CHB) and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.
|
Epidemiology Segment |
Key Insights |
|
Diagnosed Prevalent Cases of the Disease |
As estimated by GSK (2025), chronic hepatitis B affects more than 250 million people worldwide. According to Fuqiang Cui et al. (2026), 34.1 million individuals living with HBV were diagnosed globally in 2022, of whom 6.6 million received antiviral treatment, highlighting the substantial diagnosed patient population and ongoing treatment gap. |
|
Gender-Specific Cases of the Disease |
According to Ruth Simmons et al. (2024), approximately two-thirds of individuals living with chronic hepatitis B in England were male, while one-third were female. As reported by Statens Serum Institut (2023), women represented 57% of reported chronic hepatitis B cases, primarily reflecting routine antenatal screening practices. |
|
Age-Specific Cases of the Disease |
As reported by Ruth Simmons et al. (2024), 68% of individuals living with chronic hepatitis B in England were younger than 50 years. According to Statens Serum Institut (2023), the median age of reported chronic hepatitis B cases was 36 years (range: 19–78 years), indicating a considerable burden among the adult population. |
|
Ethnicity-Wise Cases of the Disease |
According to Ruth Simmons et al. (2024), more than 83% of chronic hepatitis B infections in England occurred among ethnic groups other than White British, including 23% in Black ethnic groups, 21% in other White ethnic groups, and 19% in Asian ethnic groups. |
|
Mortality and Survival Analysis of the Disease |
According to the Centers for Disease Control and Prevention (CDC) (2022), chronic hepatitis B and chronic hepatitis C together cause approximately 1.3 million deaths annually due to liver disease and liver cancer. As reported by Fuqiang Cui et al. (2026), HBV accounted for approximately 1.1 million deaths worldwide in 2022. |
Type-Specific Disease Burden and Epidemiology Analysis
|
Disease Type |
Prevalence |
|
HBeAg-Positive Chronic Hepatitis B |
Represents a major proportion of chronic hepatitis B cases during the active replicative phase and is commonly associated with higher viral activity and an increased disease burden. |
|
HBeAg-Negative Chronic Hepatitis B |
Represents a significant share of chronic hepatitis B cases, particularly among patients with persistent infection, and contributes substantially to the long-term epidemiological burden of the disease. |
Read more about this report - Request a Free Sample
Country-wise Chronic Hepatitis B (CHB) Epidemiology
The chronic hepatitis B (CHB) epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.
|
Country |
Key Insights |
|
United States |
According to the American Liver Foundation (2025), an estimated 850,000 to 2.2 million people in the United States are living with chronic hepatitis B infection. As reported by the Centers for Disease Control and Prevention (CDC) (2022), chronic hepatitis B and chronic hepatitis C together account for approximately 1.3 million deaths annually due to liver disease and liver cancer. |
|
Germany |
Chronic hepatitis B remains an important public health concern in Germany, with continued epidemiological surveillance supporting disease monitoring, early diagnosis, and long-term management across the population. |
|
France |
According to Sandra Bivegete et al. (2023), hepatitis B prevalence among the general population in France was reported at 0.0%, while the prevalence among men who have sex with men was 0.2%, reflecting a comparatively low epidemiological burden in the evaluated populations. |
|
Italy |
As reported by Giuseppina Brancaccio et al. (2023), the prevalence of chronic hepatitis B surface antigen carriers in Italy declined from nearly 3% during the 1980s to less than 0.6%, reflecting the long-term impact of the national hepatitis B vaccination program. |
|
Spain |
Chronic hepatitis B epidemiology in Spain continues to be evaluated through surveillance and public health monitoring to support disease burden assessment and healthcare planning. |
|
United Kingdom |
According to the UK Security Agency (2024), approximately 206,000 people in England are living with chronic hepatitis B, corresponding to a prevalence of 0.45%. As estimated by Ruth Simmons et al. (2024), approximately 268,767 individuals were living with chronic hepatitis B in England, representing a prevalence of 0.58%. |
|
Japan |
According to GSK (2025), chronic hepatitis B causes approximately 4,000 deaths annually in Japan, demonstrating the continued mortality burden associated with chronic HBV infection. |
|
India |
According to Ekta Gupta et al. (2025), the overall HBV prevalence in India was 0.95%, with approximately 29 million individuals living with HBV. As reported by Ekta Gupta et al. (2025), nearly 50% of chronic HBV infections occur among adults aged 30–54 years, while approximately 12% occur in children. |
Key Market Gaps, Untapped Opportunities, and Emerging Growth Areas in the Regional Disease Epidemiology Landscape
Despite improved awareness and expanded antiviral treatment availability, substantial gaps remain in the regional epidemiology landscape of chronic hepatitis B (CHB). Underdiagnosis caused by inadequate screening programs, limited access to confirmatory molecular diagnostics, and delayed linkage to care continues to hinder disease management. Significant opportunities exist in expanding population-based screening, strengthening maternal and neonatal prevention strategies, improving surveillance systems, and increasing access to early diagnosis and antiviral therapy. Advances in functional cure research and precision monitoring are expected to enhance disease management and support future epidemiological improvements across the evaluated regions.
Chronic Hepatitis B (CHB): Treatment Overview
Chronic hepatitis B (CHB) treatment focuses on suppressing hepatitis B virus replication, reducing liver inflammation, and preventing disease progression and complications. First-line therapy primarily includes long-term nucleoside analogs and nucleotide analogs, such as entecavir and tenofovir, while pegylated interferon-alpha may be considered for selected patients with favorable clinical characteristics. Regular monitoring of viral load, liver function, and disease activity is essential to evaluate treatment response and guide therapy adjustments. Emerging therapeutic approaches aim to achieve a functional cure by targeting viral suppression and restoring immune control over HBV infection.
Key Questions Answered
- What is the current and projected burden of chronic hepatitis B (CHB) across the 8 major markets?
- Which countries across the 8 major markets account for the highest chronic hepatitis B (CHB) patient populations and fastest growth rates?
- What is the diagnosed versus undiagnosed patient population of chronic hepatitis B (CHB) across key countries in the 8 major markets?
- Which countries demonstrate the largest gaps in screening, early diagnosis, and disease awareness of chronic hepatitis B (CHB) across the 8 major markets?
- What are the major drivers contributing to the increasing burden of chronic hepatitis B (CHB) across the 8 major markets?
- How do major comorbidities and risk factors influence chronic hepatitis B (CHB) epidemiology trends across the 8 major markets?
- What are the regional trends in advanced disease progression, treatment uptake, and patient management of chronic hepatitis B (CHB) across the 8 major markets?
- Which patient segments represent the highest unmet clinical need in the chronic hepatitis B (CHB) landscape across the 8 major markets?
- Which therapeutic areas linked to chronic hepatitis B (CHB) are expected to witness the strongest growth opportunities across the 8 major markets?
- How is the chronic hepatitis B (CHB) epidemiology landscape expected to evolve over the next 5 to 10 years across the 8 major markets?
- Which countries across the 8 major markets offer the most attractive market opportunities based on chronic hepatitis B (CHB) epidemiology and healthcare infrastructure?
- Which epidemiological trends are expected to influence future drug development and market access strategies for chronic hepatitis B (CHB) across the 8 major markets?
Scope of the Chronic Hepatitis B (CHB) Epidemiology Report
- The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of chronic hepatitis B (CHB) based on several factors.
- Chronic Hepatitis B (CHB) Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
- The chronic hepatitis B (CHB) report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.
Related Reports
Pricing Plans
Upto 15% Off
USD
-
$1999 $1799
-
$2999 $2699
-
$4399 $3739
-
$5799 $4929
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Report Features |
Details |
|
Base Year |
2025 |
|
Historical Period |
2019-2025 |
|
Forecast Period |
2026-2035 |
|
Epidemiology Statistics Provided |
|
|
Segmentation Provided |
|
|
Geographies Covered |
|
Datasheet
One User
USD 1,999
USD 1,799
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 2,999
USD 2,699
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 4,399
USD 3,739
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 5,799
USD 4,929
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
